




DRUG DISCOVERY

The Outlook For RNAi

Accelerating drug discovery and the development of RNAi therapeutics

By Dr CL Barton

 [Table of Contents](#)

Dr Cheryl L Barton

Dr CL Barton has over 10 years practical pharmaceutical research experience with a leading pharmaceutical company and Pan-European Pharmaceutical analyst with a European Bank.

Dr CL Barton Ltd. aims to provide independent, tailor-made, pharmaceutical thematic research to investment houses. Where applicable the research reports combine independent scientific analysis with patients- and prescription-based models to forecast the potential sales growth of key developmental drugs and isolate the key drivers within the pharmaceutical sector. For more details visit www.pharmavision.co.uk

Copyright © 2005 Business Insights Ltd
This Management Report is published by Business Insights Ltd. All rights reserved.
Reproduction or redistribution of this Management Report in any form for any purpose is expressly prohibited without the prior consent of Business Insights Ltd.

The views expressed in this Management Report are those of the publisher, not of Business Insights. Business Insights Ltd accepts no liability for the accuracy or completeness of the information, advice or comment contained in this Management Report nor for any actions taken in reliance thereon.

While information, advice or comment is believed to be correct at the time of publication, no responsibility can be accepted by Business Insights Ltd for its completeness or accuracy.

Table of Contents

The Outlook for RNAi

Executive Summary	12	
Current RNA technologies	12	
Design, production and delivery of RNAi	13	
The future of RNAi in research and drug discovery	14	
The future of RNAi drug therapies	15	
Emerging RNA technologies and future trends	16	
Patents and strategic alliances in RNAi technology	17	
RNAi markets and trends	18	
Chapter 1	Current RNA technologies	20
Summary		20
Introduction		21
History of RNAi		21
From DNA to RNA to proteins		22
mRNA regulation		23
Gene expression		24
Antisense technology		25
Oligonucleotides (OGNs)		26
Peptide nucleic acids (PNAs)		28
Locked nucleic acids (LNA)		28
Triple helix DNA or triple helix-forming oligonucleotides (TFOs)		30
Ribozymes		31
DNAzymes		32
Aptamers		33
RNA interference		33
siRNAs versus dsRNA		36
siRNAs versus shRNA		36
Conclusions		38

Chapter 2	Design, production and delivery of RNAi	42
Summary		42
Introduction		43
Cost-effective RNA design		43
Cost-effective synthesis of siRNA		45
Chemical synthesis		47
Conclusions		49
<i>In vitro</i> transcription		50
DICER reaction		51
Expression vectors		52
DNA-directed RNAi (ddRNAi)		53
Expressed interfering RNA (eiRNA)		55
Conclusions		56
Improvements in siRNA stability		57
Chemical modifications		57
Formulation modifications		59
Small molecule conjugation		59
Synthetic vector systems		61
Conclusion		62
RNAi delivery options		63
Viral vectors		65
Conclusions		66

Chapter 3	The future of RNAi in research and drug discovery	70
Summary		70
Introduction		71
Applications of RNAi in research		72
Functional genomics		72
Signaling pathways		75
Applications of RNAi in drug discovery		76
Gene expressions studies		76
Target validation		81
Toxicogenomics		83
Applications of RNAi in drug development		85
Transgenics		86
The impact of RNAi in R&D		92

Strategic alliances, 2003-2005	168
Acuity Pharmaceuticals (Philadelphia, PA, US)	168
Patent position	168
Strategic alliances, 2003-2005	169
Atugen AG (Dresden, Germany)	169
Patent position	169
Strategic alliances, 2003-2005	169
CytRx Labs (Los Angeles, MA, USA)	170
Patent position	171
Strategic alliances, 2003-2005	171
Intradigm (Rockville, MD, USA)	172
Nucleonics Inc. (Horsham, PA, USA)	172
Future impact of IP on RNAi research	173

Chapter 7 RNAi markets and trends 176

Summary	176
Introduction	177
The RNAi market	178
Market size and future trends	180
siRNA synthesis and delivery	182
RNAi reagents	183
RNAi in drug discovery and target validation	184
RNAi therapeutics	185

Chapter 8 Appendix 190

Acknowledgements	190
Index	191
Bibliography	193
Glossary	201
References	205

List of Figures

Figure 1.1:	History of RNAi	22
Figure 1.2:	Schematic of DNA, genes and proteins	23
Figure 1.3:	Schematic of gene splicing	24
Figure 1.4:	Major mechanisms for antisense OGN action	25
Figure 1.5:	Mechanism of preventing translation using OGN technology	27
Figure 1.6:	Chemical structure of PNA versus DNA	28
Figure 1.7:	Chemical structure of LNA versus RNA	29
Figure 1.8:	Mechanism of preventing translation using triple helix DNA technology	30
Figure 1.9:	Mechanism of preventing translation using ribozymes	31
Figure 1.10:	Schematic of the mechanism of gene silencing by RNAi	34
Figure 1.11:	Schematic of the mechanism of shRNAs	36
Figure 2.12:	Advantages and disadvantages of siRNA synthesis methods	46
Figure 2.13:	<i>In vitro</i> transcription of siRNAs	50
Figure 2.14:	DICER digestion of dsRNAs	52
Figure 2.15:	psiRNA plasmid vector system	53
Figure 2.16:	Mechanism of ddRNAi	54
Figure 2.17:	Chemical modifications of siRNAs increase stability and PK	57
Figure 2.18:	Chol- siRNAs improve tissue uptake and PK	60
Figure 2.19:	Intradigm's nano-delivery technology TargeTran	61
Figure 2.20:	Summary of viral vector advantages and disadvantages	65
Figure 3.21:	The application of TCA in gene expression	77
Figure 3.22:	Optimization of lead compounds with siRNAs	82
Figure 3.23:	Comparison of gene expression profiles to optimize lead compounds	83
Figure 3.24:	Investigation of the intracellular mechanism of Endothelin A receptor	85
Figure 3.25:	Schematic of knock-out and knock-down transgenics	87
Figure 3.26:	Heritable suppression of Neil-1 in mouse model	88
Figure 3.27:	ArteMice™ RNAi <i>in vivo</i> in 4 months	89
Figure 3.28:	Artemis Pharmaceutical timelines for transgenic animals	89
Figure 3.29:	Status leptinR knockdown using shRNAs	91
Figure 3.30:	Impact of RNAi in R&D	92
Figure 4.31:	Antisense drugs currently in clinical development	98
Figure 4.32:	RNAi drugs currently in clinical development	100
Figure 4.33:	Development of AMD	102
Figure 4.34:	siRNA targeting VEGF reduces blood vessel growth in the cornea	103
Figure 4.35:	Lead siRNA candidates block HCV replication	109
Figure 4.36:	HCV target destruction in mouse liver	110
Figure 4.37:	Efficacy of HIV drug <i>in vitro</i>	112
Figure 4.38:	<i>In vivo</i> efficacy of direct RNAi for RSV	115
Figure 4.39:	Systemic siRNA leads to significant reduction in apolipoproteins	134
Figure 5.40:	Conventional RISC silencing pathways and RISC pathway using “On-Target” siRNA reagents	144
Figure 5.41:	siRNA RISC process using “On-Target plus” siRNA Reagents	145
Figure 5.42:	Schematic representation of aptazyme development	152
Figure 6.43:	Key RNA-based companies targeting RNAi reagents	157
Figure 6.44:	Key RNA-based companies targeting therapeutic agents	159
Figure 6.45:	Sirna Therapeutics' IP portfolio and therapeutic areas	167

Figure 7.46:	RNAi market segments, 2004	181
Figure 7.47:	Growth in the RNAi market 2004-2010	181
Figure 7.48:	Alliances in RNAi R&D	184
Figure 7.49:	Potential value of therapy areas targeted by RNAi therapeutics, 2004 & 2010	186

List of Tables

Table 1.1:	Advantages and disadvantages of OGN technology	26
Table 1.2:	Advantages and disadvantages of modified OGNs	29
Table 1.3:	Advantages and disadvantages of TFOs	31
Table 1.4:	Advantages and disadvantages of ribozymes	32
Table 1.5:	Advantages and disadvantages of DNAzymes	32
Table 1.6:	Advantages and disadvantages of aptamers	33
Table 1.7:	Genes crucial for RNAi in model organisms	35
Table 1.8:	Advantages of RNAi	37
Table 1.9:	Disadvantages of RNAi	38
Table 2.10:	Algorithms available for designing siRNAs	44
Table 2.11:	Class of functional RNA molecule	45
Table 2.12:	Companies offering siRNA synthesis	48
Table 2.13:	Advantages of ddRNAi versus siRNA	55
Table 2.14:	Advantages of eiRNA versus siRNAs	56
Table 3.15:	Commercial siRNA libraries	79
Table 4.16:	Antiviral siRNA targets	108
Table 4.17:	RNAi-based targeted therapies	119
Table 4.18:	Examples of RNAi targets for neuronal pain	125
Table 4.19:	Chemotherapeutic siRNA targets	128
Table 5.20:	Animal miRNA genes with genetically assigned functions	147
Table 6.21:	RNA patents registered worldwide up to March 2005	155
Table 7.22:	Companies involved in RNAi technologies, A-M	179
Table 7.23:	Companies involved in RNAi technologies, N-Z	180
Table 7.24:	Sales forecasts for total RNAi market, 2004-2015	182
Table 7.25:	Sales forecasts for siRNA synthesis and delivery, 2004-2015	183
Table 7.26:	Sales forecasts for RNAi reagents, 2004-2015	183
Table 7.27:	Sales forecasts for RNAi in drug discovery & target validation, 2004-2015	185
Table 7.28:	Sales forecasts for RNAi therapeutics, 2004-2015	187
Table 7.29:	Sales forecasts for RNAi therapeutic drugs launched 2010-2015	188